Skip to product information
1 of 1

Biotin Mouse Anti-Human CD110 Antibody (S-3014)

Biotin Mouse Anti-Human CD110 Antibody (S-3014)

Catalog Number: S0B80111 Application: FCM Reactivity: Hu Conjugation: Biotin Brand: Starter
Price:
Regular price $135 USD
Regular price Sale price $135 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen CD110
Synonyms Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; TPOR; MPL
Location Cell membrane
Accession P40238
Clone Number S-3014
Antibody Type Mouse mAb
Isotype IgG2a,k
Application FCM
Reactivity Hu
Positive Sample Human PBMC
Purification Protein A
Concentration 0.2 mg/ml
Conjugation Biotin
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, 0.03% Proclin 300

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 1.25μl per million cells in 100μl volume Hu

Background

CD110, also known as thrombopoietin receptor (TPOR) or MPL (myeloproliferative leukemia protein), is a 635-amino-acid, single-pass type I transmembrane glycoprotein belonging to the hematopoietic cytokine receptor superfamily, whose extracellular N-terminal region binds thrombopoietin (TPO) with high affinity to activate JAK2/STAT, MAPK and PI3K-AKT signaling cascades that drive megakaryocyte proliferation, differentiation and platelet production, while its cytoplasmic C-terminal tail contains critical motifs for internalization and negative feedback regulation; physiologically expressed on hematopoietic stem cells, megakaryocytes, platelets and endothelial cells, CD110 is essential for steady-state and stress hematopoiesis, and genetic alterations—such as MPL W515L/K activating mutations or CALR exon 9 mutations that create neomorphic ligand binding—lead to ligand-independent signaling, constitutive activation and the development of myeloproliferative neoplasms, making CD110 a key diagnostic marker and therapeutic target for small-molecule JAK inhibitors and TPO receptor agonists/antagonists in thrombocytopenias and myelofibrosis.

Picture

FC

Flow cytometric analysis of human CD110 expression on human PBMC. Human PBMC were stained with FITC Mouse Anti-Human CD61 Antibody and either Biotin Mouse IgG2a, k Isotype Control (left panel) or SDT Biotin Mouse Anti-Human CD110 Antibody (right panel) at 1.25 μl/test followed by Sav-PE. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.